Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07187973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 10 to 11
  2. Study sites: 9 to 10
  3. Study sites: 8 to 9
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 3 of 14 entries
  4. Site contacts updated at 1 of 8 sitesv10
  5. Study sites: 7 to 8v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 6 to 7v8
  2. Study sites: 5 to 6v7
  3. Study sites: 4 to 5v6
  4. Study sites: 3 to 4v5
  5. Study sites: 1 to 3v4
  6. Start date changed from estimate of Dec 2025 to Jan 6, 2026v3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2025 to Dec 2025
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.
Trial Details
NCT Number NCT07187973
Lead Sponsor Disc Medicine, Inc
Conditions
(from sponsor)		 Sickle Cell Disease
Related terms Anemia, Sickle Cell
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov